Motus GI Holdings (DB:7M4) - Cotización, noticias y análisis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Resumen de acción 7M4

Operates as a medical technology company in the United States.

Acerca de la empresa

Análisis fundamental de 7M4
Puntuación del snowflake
Valoración	0/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	0/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 142.15%

Los beneficios han crecido un 5.1% al año en los últimos 5 años

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($364K)

Acciones altamente ilíquidas

Patrimonio neto negativo

Los accionistas han sido diluidos sustancialmente en el último año

+ 3 riesgos adicionales

Competidores de Motus GI Holdings, Inc.

MagForce

XTRA:MF6

€3.6m

elexxion

XTRA:E8X

€3.1m

MagForce

DB:MF6

€366.9k

Audientes

DB:AUG

€6.9m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Motus GI Holdings
Precios históricos de las acciones
Precio actual de la acción	US$8.25
Máximo en las últimas 52 semanas	US$15.90
Mínimo de 52 semanas	US$5.50
Beta	1.49
1Cambio en 1 mes	0%
Variación en 3 meses	6.59%
Cambio de 1 año	-38.20%
3Variación en 3 años	n/a
Variación en 5 años	n/a
Variación desde la OPV	-98.44%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	7M4	DE Medical Equipment	Mercado DE
7D	0%	-3.7%	-1.9%
1Y	-38.2%	6.6%	12.3%

Rentabilidad vs. Industria: 7M4 obtuvo unos resultados inferiores a los del sector German Medical Equipment , que el año pasado arrojó un rendimiento del -13.6%.

Rentabilidad vs. Mercado: 7M4 obtuvo unos resultados inferiores a los del mercado German, que fue del -0.3% el año pasado.

Volatilidad de los precios

Is 7M4's price volatile compared to industry and market?
7M4 volatility
7M4 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de 7M4 ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 7M4 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2008	46	Mark Pomeranz	www.motusgi.com

Resumen de fundamentos de Motus GI Holdings, Inc.

¿Cómo se comparan los beneficios e ingresos de Motus GI Holdings con su capitalización de mercado?
Estadísticas fundamentales de 7M4
Capitalización bursátil	€1.42m
Beneficios(TTM)	-€12.69m
Ingresos (TTM)	€336.08k

4.1x

Ratio precio-ventas (PS)

-0.1x

Ratio precio-beneficio (PE)

¿Está 7M4 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 7M4
Ingresos	US$364.00k
Coste de los ingresos	US$754.00k
Beneficio bruto	-US$390.00k
Otros gastos	US$13.35m
Beneficios	-US$13.74m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-8.88
Margen bruto	-107.14%
Margen de beneficio neto	-3,775.82%
Ratio deuda/patrimonio	-370.7%

¿Cómo se ha desempeñado 7M4 a largo plazo?

Ver rendimiento histórico y comparativa

This company listing is no longer active

Resumen de acción 7M4

Recompensas

Análisis de riesgos

Competidores de Motus GI Holdings, Inc.

XTRA:MF6

€3.6m

XTRA:E8X

€3.1m

DB:MF6

€366.9k

DB:AUG

€6.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

Recent updates

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

New major risk - Financial position

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$1.86 loss in 2Q 2022)

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.86 loss in 1Q 2022)

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$1.86 loss per share (vs US$1.99 loss in 2Q 2021)

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: US$0.093 loss per share (vs US$0.26 loss in 1Q 2021)

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Full year 2021 earnings released: US$0.54 loss per share (vs US$0.60 loss in FY 2020)

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Forecast to breakeven in 2025

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Motus GI Holdings, Inc.

4.1x

-0.1x

Beneficios e Ingresos